Eric A. Hughes - 05 Mar 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role: Executive Vice President, Global R&D and Chief Medical Officer.
Signature: /s/ Dov Bergwerk as attorney-in-fact for Eric A. Hughes
Issuer symbol: TEVA
Transactions as of: 05 Mar 2025
Net transactions value: $0
Form type: 4
Filing time: 07 Mar 2025, 16:16:45 UTC
Previous filing: 06 Mar 2025
Next filing: 16 Jun 2025
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TEVA	Restricted Share Units	Award	$0	+78,616		$0.000000	78,616	05 Mar 2025	Ordinary Shares	78,616		Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2	Restricted share units were granted on March 5, 2025, with 19,654 vesting on each of March 5, 2026, March 5, 2027 and March 5, 2028 and March 5, 2029.
F3	The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Remarks:

Executive Vice President, Global R&D and Chief Medical Officer.